The use of hepatitis B vaccine as booster for donors immune to HBV for the production of hepatitis B immunoglobulin (HBIG).
Forty nine blood donors immune to HBV volunteered to receive a single dose of hepatitis B vaccine (HEVAC B from Institut Pasteur Production). The initial mean level of anti-HBs was 20 IU/ml (from 5 to 75 IU/ml). The maximum level was observed at the consecutive plasma donation usually 1 month and a half after the vaccine injection. The mean maximum level was 188 IU/ml (from 7 to 800 IU/ml) i.e. an increase of 9 times the initial level. Six donors developed a very weak immune response (inferior to twice the initial level). In the 43 others, anti-HBs levels remained higher than initial level 6 months after the vaccine injection. One year later (study conducted in 25 subjects) 56% had anti-HBs levels superior to 3.6 to 16 times the original level. Such booster responses are of considerable practical importance for increasing anti-HBs titers in human donors for producing HBIG.
D000328:Adult; D005260:Female; D006510:Hepatitis B Antibodies / Q000032:analysis; D017325:Hepatitis B Vaccines; D006515:Hepatitis B virus / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary; D007136:Immunoglobulins / Q000096:biosynthesis*; D008297:Male; D008875:Middle Aged; D014765:Viral Vaccines / Q000276:immunology*
D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D007136:Immunoglobulins; D014765:Viral Vaccines